CONGRESS PRESENTATIONS

CONGRESS PRESENTATIONS

AIDS 2022

24th International AIDS Conference

July 29 - August 2, 2022
Hybrid

  • Cabotegravir

    Chamay N, et al.

    Long-acting Cabotegravir + Rilpivirine Injection Site Reactions: Pooled Week 96 Results. Presented at AIDS 2022, July 29-August 2, 2022, Montreal, Canada, and virtually. E-poster.

    View Poster

    Elliot ER, et al.

    Long-acting Cabotegravir + Rilpivirine In Older Adults: Pooled Phase 3 Week 96 Results. Presented at AIDS 2022, July 29-August 2, 2022, Montreal, Canada, and virtually. E-poster.

    View Poster

    Han K, et al.

    Pharmacokinetics (PK) and Tolerability of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Intramuscular (IM) Injections to the Vastus Lateralis (Lateral Thigh) Muscles of Healthy Adult Participants. Presented at AIDS 2022, July 29-August 2, 2022, Montreal, Canada, and virtually. E-poster.

    View Poster

    Jonsson- Oldenbüttel C, et al.

    Safety and effectiveness outcomes from the Carisel study: Phase 3b hybrid-3 implementation study integrating cabotegravir + rilpivirine long-acting into European clinical settings. Presented at AIDS 2022, July 29-August 2, 2022, Montreal, Canada, and virtually. E-poster.

    View Poster

    Karver TS, et al.

    Factors Associated with Healthcare Providers’ Preference for Forgoing an Oral lead-in Phase when Initiating Long-acting Injectable ART in the SOLAR Clinical Trial. Presented at AIDS 2022, July 29-August 2, 2022, Montreal, Canada, and virtually. E-poster.

    View Poster

    Patel P, et al.

    Week 96 weight and lipid changes from baseline among participants receiving cabotegravir and rilpivirine long-acting or comparator therapy in the ATLAS-2M and FLAIR studies. Presented at AIDS 2022, July 29-August 2, 2022, Montreal, Canada, and virtually. E-poster.

    View Poster

    Teichner P, et al.

    “Give it a Shot”: Best Practices from HCPS for Administering Long-acting CAB+RPV. Presented at AIDS 2022, July 29-August 2, 2022, Montreal, Canada, and virtually. E-poster.

    View Poster

    Wyen C, et al.

    Initiating long-acting cabotegravir and rilpivirine in a real-world setting – clinical characteristics and switch reasons from PLHIV and health care provider perspective in the German CARLOS cohort. Presented at AIDS 2022, July 29-August 2, 2022, Montreal, Canada, and virtually. E-poster.

    View Poster

    Beckham SW, et al.

    Audience segmentation of preferences for long-acting injectable prep among US MSM: a latent class analysis. Presented at AIDS 2022, July 29-August 2, 2022, Montreal, Canada, and virtually. E-poster.

    View Poster

    Beckham SW, et al.

    Willingness and preferences for long-acting injectable prep among US men who have sex with men. Presented at AIDS 2022, July 29-August 2, 2022, Montreal, Canada, and virtually. E-poster.

    View Poster

    Blissett R, et al.

    Supporting achievement of the State of Georgia’s 25% HIV incidence reduction target among MSM: A mathematical model to evaluate the potential impact of long-acting preexposure prophylaxis in Atlanta. Presented at AIDS 2022, July 29-August 2, 2022, Montreal, Canada, and virtually. E-poster.

    View Poster

    Han K, et al.

    Selection of Cabotegravir Dosing Regimens for HIV Treatment and Pre-exposure Prophylaxis (PrEP) in Adolescents by Leveraging Adult Data. Presented at AIDS 2022, July 29-August 2, 2022, Montreal, Canada, and virtually. E-poster.

    View Poster

  • Dolutegravir

    Kowalska JD, et al.

    A multicentre observational study to determine the safety and effectiveness of dolutegravir (DTG) use during pregnancy: Data from DOLOMITE-NEAT ID Network study. Presented at AIDS 2022, July 29-August 2, 2022, Montreal, Canada, and virtually. E-poster.

    View Poster

    Kumar PN, et al.

    Improvements in Patient-Reported Outcomes in Older Adults Aged 50 Years With HIV-1 After Switching to a 2-Drug Regimen of Fixed-Dose Combination DTG/3TC: 48-Week Results from the SALSA Study. Presented at AIDS 2022, July 29-August 2, 2022, Montreal, Canada, and virtually. E-poster.

    View Poster

    Llibre JM, et al.

    Changes in Inflammatory Biomarkers and Baseline Variables After Switching to Dolutegravir/Lamivudine (DTG/3TC) in 2 Randomized Clinical Trials of Virologically Suppressed Adults: 48-Week Pooled Analysis. Presented at AIDS 2022, July 29-August 2, 2022, Montreal, Canada, and virtually. E-poster.

    View Poster

    Pierone G, et al.

    Switching to dolutegravir/lamivudine two-drug regimen: durability and virologic outcomes in routine U.S. clinical care. Presented at AIDS 2022, July 29-August 2, 2022, Montreal, Canada, and virtually. E-poster.

    View Poster

    Schneider S, et al.

    Treatment experience of single-tablet dolutegravir/lamivudine in the United States: results from the ‘real-world outcomes with dolutegravir-based two-drug-regimens for the treatment of HIV-1’ (TANDEM STUDY). Presented at AIDS 2022, July 29-August 2, 2022, Montreal, Canada, and virtually. E-poster.

    View Poster

    Scholten S, et al.

    Efficacy and Safety of Switching to Dolutegravir/Lamivudine by Baseline Regimen in Virologically Suppressed Adults: 48-Week Pooled Analysis. Presented at AIDS 2022, July 29-August 2, 2022, Montreal, Canada, and virtually. E-poster.

    View Poster

    Walmsley S, et al.

    Efficacy and Safety of Switching to Dolutegravir/Lamivudine (DTG/3TC) in Treatment-Experienced, Virologically Suppressed PLHIV Aged 50 Years: Pooled Results From the TANGO and SALSA Studies. Presented at AIDS 2022, July 29-August 2, 2022, Montreal, Canada, and virtually. Poster.

    View Poster

    Wang R, et al.

    Low Level of Virologic Failure and Resistance in ART-Experienced, Integrase Inhibitor-Naïve Participants Receiving Dolutegravir (DTG) and Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Combined Regimens: 10-Year Follow-up in the SAILING Study. Presented at AIDS 2022, July 29-August 2, 2022, Montreal, Canada, and virtually. E-poster.

    View Poster

  • Fostemsavir

    Aberg J, et al.

    Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults With HIV-1: Week 240 Results of the Phase 3 BRIGHTE Study. Presented at AIDS 2022, July 29-August 2, 2022, Montreal, Canada, and virtually. E-poster.

    View Poster

  • Disease State

    Benn P, et al.

    A Study Evaluating the Safety, Tolerability and Pharmacokinetics of a High-Concentration (CAB 400mg/mL) Cabotegravir Long-Acting Injectable Formulation Following Subcutaneous and Intramuscular Administration in Healthy Adult Participants. Presented at AIDS 2022, July 29-August 2, 2022, Montreal, Canada, and virtually. Poster.

    View Poster

    De La Mora L, et al.

    Do ART and Chemsex Drugs Get Along? Potential Drug-Drug Interactions in a Cohort of HIV-Positive Chemsex Users. Presented at AIDS 2022, July 29-August 2, 2022, Montreal, Canada, and virtually. E-poster.

    View Poster

    Drumright LN, et al.

    Differences in Burden of Internalized HIV Stigma by Race/Ethnicity among People with HIV (PWH) Living in the US. Presented at AIDS 2022, July 29-August 2, 2022, Montreal, Canada, and virtually. E-poster.

    View Poster

    Harrison S, et al.

    Implementation of a Ridesharing Intervention to Address Transportation Vulnerability for People Living With HIV in the Southern United States: Qualitative Findings on Acceptability and Feasibility. Presented at AIDS 2022, July 29-August 2, 2022, Montreal, Canada, and virtually. E-poster.

    View Poster

    Hung P, et al.

    Does Travel Time Matter?: Transportation Vulnerability and Access to HIV Care Among People Living With HIV in South Carolina. Presented at AIDS 2022, July 29-August 2, 2022, Montreal, Canada, and virtually. Poster.

    View Poster

    McKay T, et al.

    U=U Awareness Promotes Engagement in HIV Care Among HIV Negative Men Who Have Sex With Men in Mississippi and Alabama. Presented at AIDS 2022, July 29-August 2, 2022, Montreal, Canada, and virtually. Poster.

    View Poster

    Park S, et al.

    Bridging the gap between patient perceptions and delivered care among people living with HIV in the Asian region. Presented at AIDS 2022, July 29-August 2, 2022, Montreal, Canada, and virtually. Poster.

    View Poster

This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their license. In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.

My MSL

Enter zip code to find your MSL contact.